4892.T
Cyfuse Biomedical K.K.
グロース · 医薬品 · 医薬品 · JP
JPY 587.00
+4.45%Year over year
Reported trailing growth
- Revenue
- +325.9%
- EBITDA
- —
- EBIT
- +7.6%
- EPS
- +16.9%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- +31.3%
- EBITDA
- —
- EPS
- -53.8%
Three-year CAGR
- Revenue
- -15.0%
- EBITDA
- +7.8%
- EBIT
- +7.6%
- Net income
- +12.5%
- EPS
- +19.9%
- Free cash flow
- +24.3%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026